Angiogenesis and VEGF in AML patients before and after treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138805122192N5

Enrollment

Registered

2010-01-04

Start date

2009-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukaemia. Acute myeloid leukaemia

Interventions

Chemotherapy with 7 days of cytarabine 100mg/m2 and 3 day treatment of danorobicin 45mg/m2.

Treatment - Drugs

Chemotherapy with 7 days of cytarabine 100mg/m2 and 3 day treatment of danorobicin 45mg/m2

Eligibility

Sex/Gender

All

Age

12 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: New AML case, age less than 65, no previous treatment Exclusion: Vital organ impairment, not tolerating standard regimen

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
VEGF level after treatment. Timepoint: 1 day before treatment and about one month later at the time of blood elements recovery. Method of measurement: mRNA in Peripheral blood with ELISA and bone marrow aspirate with RT-PCR.;Bone marrow angiogenesis with microvessel density. Timepoint: 1 Day before and After treatment when blood elements are recovered. Method of measurement: Anti CD34 staining on bone marrow parafine block.	—

Measure

Time frame

VEGF level after treatment. Timepoint: 1 day before treatment and about one month later at the time of blood elements recovery. Method of measurement: mRNA in Peripheral blood with ELISA and bone marrow aspirate with RT-PCR.;Bone marrow angiogenesis with microvessel density. Timepoint: 1 Day before and After treatment when blood elements are recovered. Method of measurement: Anti CD34 staining on bone marrow parafine block.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Reza Khalili Dizaji

Tabriz University of Medical Sciences

dr_kh_d@yahoo.com+98 41 1478 3672

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026